Search

Your search keyword '"Visani, L."' showing total 5 results
Start Over Author "Visani, L." Region italy
5 results on '"Visani, L."'

1. 156 (PB-063) Poster - Safety of trastuzumab deruxtecan and radiation therapy combination in HER2-positive metastatic breast cancer patients.

Author

Visani, L., Ratosa, I., Ribnikar, D., Becherini, C., Bertini, N., Bonaparte, I., Stefanovski, D., Dobnikar, N., Desideri, I., Mattioli, C., Valzano, M., Banini, M., Salvestrini, V., Bernini, M., Tommasi, C., Nori, J., Orzalesi, L., Bianchi, S., Livi, L., and Meattini, I.

Subjects
*TRASTUZUMAB, *PATIENT safety, *BREAST tumors, *CANCER patients, *CONFERENCES & conventions, *ONCOGENES, *COMBINED modality therapy
Published
2024
Full Text
View/download PDF

2. 171 (PB-078) Poster - Ductal carcinoma in situ of the breast, lessons learned after more than 10 years follow-up of a cohort of patients from a large western cancer centre.

Author

Bernini, M., Cassetti, D., Tommasi, C., Gaggelli, I., Manetti, F., Gigliucci, G., Arlia, L., Meattini, I., Livi, L., Salvestrini, V., Visani, L., Bicchierai, G., Nori Cucchiari, J., De Benedetto, D., DiNaro, F., Bianchi, S., and Orzalesi, L.

Subjects
*CANCER treatment, *CONFERENCES & conventions, *DUCTAL carcinoma, *BREAST cancer, *CARCINOMA in situ, *SPECIALTY hospitals
Published
2024
Full Text
View/download PDF

3. 170 (PB-077) Poster - Prepectoral breast reconstruction with tissue expander covered by acellular dermal matrix: results and outcomes after the first 94 procedures.

Author

Bernini, M., Cassetti, D., Tommasi, C., Gaggelli, I., Gigliucci, G., Arlia, L., Manetti, F., Meattini, I., Livi, L., Salvestrini, V., Visani, L., Bicchierai, G., Nori Cucchiari, J., De Benedetto, D., DiNaro, F., Bianchi, S., and Orzalesi, L.

Subjects
*DERMIS, *MAMMAPLASTY, *BREAST tumors, *CONFERENCES & conventions, *TISSUE expansion
Published
2024
Full Text
View/download PDF

4. 132 (PB-132) Poster - Single center analysis of safety profile and survival outcomes of intracranial radiation therapy in combination with trastuzumab-emtansine (T-DM1).

Author

Mattioli, C., Salvestrini, V., Becherini, C., Visani, L., Desideri, I., Greto, D., Olmetto, E., Scoccimarro, E., Mangoni, M., Peruzzi, A., Orsatti, C., Frosini, G., Bonaparte, I., Burchini, L., Valzano, M., Meattini, I., and Livi, L.

Subjects
*PATIENT safety, *TRASTUZUMAB, *RADIOTHERAPY, *TREATMENT effectiveness, *CONFERENCES & conventions, *OVERALL survival
Published
2024
Full Text
View/download PDF

5. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.

Author

Borghetti P, Bonù ML, Giubbolini R, Levra NG, Mazzola R, Perna M, Visani L, Meacci F, Taraborrelli M, Triggiani L, Franceschini D, Greco C, Bruni A, Magrini SM, and Scotti V

Subjects
Adult, Aged, Aged, 80 and over, Anaplastic Lymphoma Kinase genetics, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Combined Modality Therapy, DNA Mutational Analysis, ErbB Receptors genetics, Female, Humans, Italy, Lung Neoplasms genetics, Lung Neoplasms pathology, Male, Middle Aged, Mutation, Neoplasm Metastasis, Retrospective Studies, Societies, Medical, Survival Rate, Treatment Outcome, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Protein Kinase Inhibitors therapeutic use
Abstract

Purpose: To investigate the role of radiotherapy (RT) in the management of EGFR- or ALK-mutated metastatic non-small cell lung cancer (NSCLC) treated with TKI., Materials and Methods: Clinical data of 106 patients (pts) from five Institutions treated with RT concomitant to TKI were retrospectively revised. Overall survival (OS) and toxicities were analyzed as endpoints of the study., Results: Median age of pts was 65 years. TKIs were given for EGFR (81%)- or ALK (19%)-mutated metastatic NSCLC. Stereotactic RT (SRT) was delivered to 49 pts (46%). Patients with four or less metastasis were defined as oligometastatic/oligoprogressive (OM/OP); sites of RT were brain, bone, lung or others in 46%, 27%, 14% and 13%, respectively. Median OS was 23 months. At univariate analysis SRT, ECOG PS 0-1, OM/OP disease, lung sites and a TKI duration longer than median favorably affected OS (all p < 0.001). Multivariate analysis confirmed SRT (HR 0.355, CI 95% 0.212-0.595; p < 0.001) and median duration of TKI > 14 months (HR 0.17, 95% CI 0.10-0.30; p < 0.001) as independent factors related to better OS. Toxicities were rare., Conclusions: SRT seems to positively affect OS with limited toxicity in selected patients.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results